missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ SuperScript™ IV First-Strand Synthesis System

Codice prodotto. 15327696
Cambia vista
Click to view available options
Include:
Kit only
Kit with ezDNase
N. di reazioni:
200 Reactions
50 Reactions
Unit Size:
200 reazioni
200 tests
50 reazioni
4 product options available for selection
Product selection table with 4 available options. Use arrow keys to navigate and Enter or Space to select.
Product Code. Include N. di reazioni Unit Size
15327696 Kit only 50 Reactions 50 reazioni
15337696 Kit only 200 Reactions 200 reazioni
16397225 Kit with ezDNase 50 Reactions 50 reazioni
16272082 Kit with ezDNase 200 Reactions 200 tests
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 4 options available.
4 options
This item is not returnable. View return policy
Product Code. 15327696 Supplier Invitrogen™ Supplier No. 18091050
Discount Lab Supplies
Usa il codice promozionale 28170
View all promotions
 Articolo soggetto a restrizioni
Lager vorrätig
Add to basket
Edge
Add to basket

missing translation for 'validMainframeMsg'

This item is not returnable. View return policy

The SuperScript IV First-Strand Synthesis System for RT-PCR, available with or without ezDNase, is optimized for synthesis of first-strand cDNA from purified poly(A)+ or total RNA.

The SuperScript IV First-Strand Synthesis System for RT-PCR, available with or without ezDNase, is optimized for synthesis of first-strand cDNA from purified poly(A)+ or total RNA. The system includes SuperScript IV Reverse Transcriptase (RT), a proprietary MMLV mutant that produces robust and reliable cDNA synthesis in RT reactions. The SuperScript IV First-Strand Synthesis System with ezDNase has the further ability to remove potential genomic DNA contamination.

The SuperScript IV synthesis system is significantly improved over the SuperScript III-based system in inhibitor resistance, processivity, and reaction speed, while retaining all the benefits of the previous system, including increased thermostability, highly efficient full-length cDNA synthesis, and reduced RNase activity. The SuperScript IV system is designed to provide reliable, consistent, and fast cDNA synthesis in the presence of inhibitors found in a wide variety of samples that cause other currently available RTs to perform inefficiently.

The extremely simplified genomic DNA removal step of the SuperScript IV First-Strand Synthesis System with ezDNase dramatically reduces the time of the entire reverse transcription protocol and reduces possible variation in gene expression due to RNA loss or damage during conventional DNase treatment. The SuperScript IV synthesis system with ezDNase is the top choice for performance and flexibility for RT-PCR applications. We recommend it for all RT-PCR applications, especially when reproducibility and reliability is the primary concern and when inhibitors in the RNA sample may interfere with cDNA synthesis, leading to biases in gene expression studies.

Both SuperScript IV First-Strand Synthesis systems contain all components needed for RT reactions, plus an additional control gene and primers, and provide the flexibility to customize the RT set-up to fit the needs of your application.

Features of the SuperScript IV First-Strand Synthesis System include:
• Significantly improved resistance to a variety of inhibitors that can interfere with cDNA synthesis
• Robust and specific cDNA synthesis in a wide range of sample types
• A faster reverse transcriptase reaction that reduces incubation time from >50 min to 10 min
• Significantly better processivity compared to SuperScript III RT
• Simplified genomic DNA removal step (SuperScript IV synthesis system with ezDNase only)

Enzyme source
Purified from E. coli expressing the pol gene of M-MLV, modified to increase thermostability, half-life, processivity, and inhibitor resistance and to reduce RNase H activity.

Performance and quality testing
Endodeoxyribonuclease, exodeoxyribonuclease, and ribonuclease assays; and yield and length of cDNA product

Unit definition
One unit of SuperScript IV RT is the amount of enzyme required to incorporate 1 nmole of deoxyribonucleotide into acid-precipitable material in 10 min at 37°C using poly(A) oligo(dT)12-18 as a template/primer.

Unit reaction conditions
50 mM Tris-HCl (pH 8.3), 4 mM MgCl2, 10 mM DTT, 50 mM KCl, 0.5 mM dTTP, 0.4 MBq/mL [3H]-dTTP, 0.4 mM poly(A) oligo (dT)12-18 and enzyme in 20 μL for 10 min at 37°C

TRUSTED_SUSTAINABILITY

Specifications

Content And Storage

• Oligo(dT)20 , 50 μL (50 μM)
• Random hexamers, 250 μL (50 ng/μL)
• 5X RT buffer, 1 mL
• DTT, 250 μL (0.1 M)
• dNTP mix, 250 μL (10 mM)
• SuperScript IV RT, 50 μL (200 U/μL)
• Ribonuclease Inhibitor, 100 μL (40 U/μL)
• E. coli RNase H, 50 μL (2 U/μL)
• DEPC-treated water, 1.2 mL
• Total HeLa RNA, 20 μL (10 ng/μL)
• Sense Control Primer, 25 μL (10 μM)
• Antisense Control Primer, 25 μL (10 μM)

Store at -15°C to -25°C.

Formato Kit
GC-Rich PCR Performance High
Reaction Speed 10 min.
Tecnica Reverse Transcription
Optimal Reaction Temperature 50°C
Quantità Each
Reverse Transcriptase SuperScript IV
Shipping Condition Dry Ice
Da utilizzare con (applicazione) RT-PCR, Real Time PCR (qPCR)
Tipo di prodotto finale First-Strand cDNA
N. di reazioni 50 Reactions
Reaction Format Separate components
Tipo di reagente Reverse Transcription
Dimensioni (prodotto finale) Up to 12.3 kb
Starting Material RNA
Include Kit only
Show More Show Less
compliance-icons
Product Identifier
  • SuperScript IV First-Strand Synthesis System
Signal Word
  • Attenzione
Hazard Category
  • Lesione oculare grave/irritazione oculare Categoria 2
Hazard Statement
  • H319-Provoca grave irritazione oculare.
Precautionary Statement
  • P264-Lavare accuratamente dopo l'uso.
  • P280-Indossare guanti/indumenti protettivi/Proteggere gli occhi/il viso.
  • P305+P351+P338-IN CASO DI CONTATTO CON GLI OCCHI: sciacquare accuratamente per parecchi minuti. Togliere le eventuali lenti a contatto se è agevole farlo. Continuare a sciacquare.
  • P337+P313-Se l'irritazione degli occhi persiste, consultare un medico.
Supplemental information
  • MIXTURE LIST-Contain: (R*,R*)-1,4-Dimercapto-2,3-butanediol

For Research Use Only. Not for use in diagnostic procedures.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.